Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor

About this update from Beta Bionics, Inc.

IRVINE, Calif. , June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. , a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market. “This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,” said Sean Saint , President and CEO of Beta Bionics . “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available.” *User must be carb aware About Beta Bionics Beta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet® Bionic Pancreas—the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. Designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes, the iLet sets a new standard in diabetes care. For more information, visit www.betabionics.com . Important Safety Information Product for prescription only. For important safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html. Investor Relations Contact: [email protected] Media and Public Relations Contact: [email protected] Source: Beta Bionics, Inc.

View stock analysis, news, and events for Beta Bionics, Inc.